JP2018537107A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537107A5
JP2018537107A5 JP2018530743A JP2018530743A JP2018537107A5 JP 2018537107 A5 JP2018537107 A5 JP 2018537107A5 JP 2018530743 A JP2018530743 A JP 2018530743A JP 2018530743 A JP2018530743 A JP 2018530743A JP 2018537107 A5 JP2018537107 A5 JP 2018537107A5
Authority
JP
Japan
Prior art keywords
pneumococcal
fusion protein
recombinant lipidated
recombinant
lipidated fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018530743A
Other languages
English (en)
Japanese (ja)
Other versions
JP6947727B2 (ja
JP2018537107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2016/051449 external-priority patent/WO2017096486A1/en
Publication of JP2018537107A publication Critical patent/JP2018537107A/ja
Publication of JP2018537107A5 publication Critical patent/JP2018537107A5/ja
Application granted granted Critical
Publication of JP6947727B2 publication Critical patent/JP6947727B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018530743A 2015-12-10 2016-12-09 脂質化肺炎球菌抗原組成物、調製方法及び使用 Expired - Fee Related JP6947727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265525P 2015-12-10 2015-12-10
US62/265,525 2015-12-10
PCT/CA2016/051449 WO2017096486A1 (en) 2015-12-10 2016-12-09 Lipidated streptococcus pneumoniae antigen compositions, methods of preparation and use

Publications (3)

Publication Number Publication Date
JP2018537107A JP2018537107A (ja) 2018-12-20
JP2018537107A5 true JP2018537107A5 (enExample) 2020-01-23
JP6947727B2 JP6947727B2 (ja) 2021-10-13

Family

ID=59012415

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018530743A Expired - Fee Related JP6947727B2 (ja) 2015-12-10 2016-12-09 脂質化肺炎球菌抗原組成物、調製方法及び使用

Country Status (7)

Country Link
US (2) US20180360943A1 (enExample)
EP (2) EP3387006A4 (enExample)
JP (1) JP6947727B2 (enExample)
CN (1) CN108884134A (enExample)
CA (2) CA3008042A1 (enExample)
TW (2) TWI745323B (enExample)
WO (2) WO2017096486A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
CN110898217B (zh) * 2019-11-28 2023-03-28 遵义医科大学珠海校区 一种肺炎链球菌疫苗及其制备方法
IL297166A (en) 2020-04-09 2022-12-01 Valneva Austria Gmbh Compositions comprising three ospa fusion proteins for medical use
US20240026412A1 (en) * 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
CN119798389A (zh) * 2024-12-12 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5854416A (en) * 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
AU734488B2 (en) 1994-05-20 2001-06-14 Uab Research Foundation Mucosal administration of pneumococcal antigens
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
GB9614700D0 (en) 1996-07-12 1996-09-04 Medical Res Council Over-expression of proteins in E.Coli
AU2003204215B2 (en) * 1998-02-03 2007-01-11 Aventis Pasteur Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
NZ525674A (en) * 1998-02-03 2005-01-28 Ct Disease Contr & Prevention Recombinant lipidated PsaA protein, methods of preparation and use
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
US6770321B2 (en) 2002-01-25 2004-08-03 Afg Industries, Inc. Method of making transparent articles utilizing protective layers for optical coatings
WO2006127020A1 (en) 2005-05-19 2006-11-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PsaA ANTIGEN AND USES THEREOF
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US7833776B2 (en) * 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
EP3017826A1 (en) * 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
US8658176B2 (en) * 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
TW201221642A (en) * 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
US9765125B2 (en) * 2012-01-20 2017-09-19 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against Streptococcus pneumoniae
WO2013171661A2 (en) * 2012-05-15 2013-11-21 Subhash V Kapre Adjuvant formulations and methods
WO2014018904A1 (en) 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
CN116603058A (zh) * 2015-03-26 2023-08-18 Gpn疫苗有限公司 链球菌疫苗

Similar Documents

Publication Publication Date Title
Langermann et al. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.
Moreno et al. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection
US10588955B2 (en) Streptococcus pneumoniae protein antigen, and preparation method and use thereof
CN104968366B (zh) 包含一种或多种肺炎链球菌荚膜糖缀合物和含有来自流感嗜血杆菌的蛋白E和/或PilA的蛋白组分的免疫原性组合物
Larentis et al. Cloning and optimization of induction conditions for mature PsaA (pneumococcal surface adhesin A) expression in Escherichia coli and recombinant protein stability during long-term storage
JP2015505309A5 (enExample)
JP2013504556A5 (enExample)
CA2504938A1 (en) Compositions and methods for treating or preventing pneumococcal infection
Vadesilho et al. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae
US20160250283A1 (en) Compositions and methods for prophylaxis and therapy of clostridium difficile infection
Velineni et al. Characterization and protective immunogenicity of the SzM protein of Streptococcus zooepidemicus NC78 from a clonal outbreak of equine respiratory disease
Mizrachi Nebenzahl et al. Streptococcus pneumoniae cell-wall-localized phosphoenolpyruvate protein phosphotransferase can function as an adhesin: identification of its host target molecules and evaluation of its potential as a vaccine
Song et al. Bioinformatics analysis and epitope screening of a potential vaccine antigen TolB from Acinetobacter baumannii outer membrane protein
TW201731866A (zh) 脂化之肺炎鏈球菌抗原組合物、製備方法及用途
Cui et al. Construction and protective efficacy of a novel Streptococcus pneumoniae fusion protein vaccine NanAT1-TufT1-PlyD4
JP2015513314A5 (enExample)
JP7334176B2 (ja) 肺炎球菌表面タンパク質Ａ（ＰｓｐＡ）の発現
Vorobieva et al. Analysis of recombinant group B streptococcal protein ScaAB and evaluation of its immunogenicity
Gandhi et al. Towards developing a vaccine for rheumatic heart disease
Ferreira et al. DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein
Li et al. Mutagenesis and immunological evaluation of group A streptococcal C5a peptidase as an antigen for vaccine development and as a carrier protein for glycoconjugate vaccine design
Swiatlo et al. Choline‐binding proteins
WO2019129321A3 (de) Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter subunit-vakzine auf basis der hefe kluyveromyces lactis
CN107847578A (zh) 免疫原性组合物
Cecchini et al. Next generation vaccines: development of a novel Streptococcus pneumoniae multivalent protein vaccine